Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with central nervous system cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herbert Irving Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carmustine; Cyclophosphamide; Etoposide; Thiotepa

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed malignant tumors

• Anaplastic astrocytoma

• Oligodendroglioma

• Germ cell tumor

• Medulloblastoma

• Primary neuroectodermal tumor

• Esthesioneuroblastoma

• CNS lymphoma (primary or systemic disease)

• Multifocal intracranial disease allowed

• No extraneural metastases (except controlled systemic lymphoma)

• Pretreatment considerations based on tumor type

• Anaplastic astrocytoma:

• Recurrent disease

• Any treatment at diagnosis allowed (carmustine dose limited to 480 mg/m2)

• Chemotherapy not required at recurrence

• Oligodendroglioma:

• Disease response (at least minor) to conventional chemotherapy OR

• Recurrent disease

• Esthesioneuroblastoma:

• Attempted complete surgical resection

• Disease progression after radiotherapy

• Response to chemotherapy regimen comprising cyclophosphamide, etoposide, and cisplatin

• CNS lymphoma:

• Disease refractory to methotrexate OR

• Failure after initial treatment with methotrexate OR

• Considered at high risk for disease relapse despite initial response

• Radiographic or pathological confirmation of recurrent disease required

• Not eligible for other high priority national or institutional clinical studies

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG or Zubrod 0-1

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Creatinine less than 1.5 times normal

Cardiovascular:

• LVEF at least 45%

Pulmonary:

• DLCO at least 60% predicted OR

• Approval of pulmonologist

Other:

• Not pregnant or nursing

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics

• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent anticancer hormonal therapy

• No concurrent steroids as antiemetics

Radiotherapy:

• See Disease Characteristics

Surgery:

• See Disease Characteristics

Other:

• No concurrent barbiturates or acetaminophen

• Participation in other concurrent supportive care or gene therapy trials allowed